4/6
02:41 pm
agio
Agios Pharmaceuticals (AGIO) had its price target raised by JPMorgan Chase & Co. from $31.00 to $36.00. They now have a "neutral" rating on the stock.
Neutral
Report
Agios Pharmaceuticals (AGIO) had its price target raised by JPMorgan Chase & Co. from $31.00 to $36.00. They now have a "neutral" rating on the stock.
4/6
07:00 am
agio
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Low
Report
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
4/1
01:46 pm
agio
Agios Pharmaceuticals (AGIO) had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $32.00. They now have a "neutral" rating on the stock.
Low
Report
Agios Pharmaceuticals (AGIO) had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $32.00. They now have a "neutral" rating on the stock.
4/1
09:00 am
agio
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Low
Report
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
3/31
12:35 pm
agio
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything [Yahoo! Finance]
Medium
Report
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything [Yahoo! Finance]
3/31
12:35 pm
agio
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today [Yahoo! Finance]
Medium
Report
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today [Yahoo! Finance]
3/31
09:00 am
agio
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money
Low
Report
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money
3/31
07:30 am
agio
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA [Yahoo! Finance]
Low
Report
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA [Yahoo! Finance]
3/31
07:00 am
agio
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
High
Report
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
3/25
09:00 am
agio
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation
Medium
Report
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation
3/22
01:04 am
agio
Low
Report
3/18
12:55 pm
agio
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why [Yahoo! Finance]
3/18
09:00 am
agio
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Low
Report
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
3/17
09:00 am
agio
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
Low
Report
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
3/11
09:00 am
agio
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Low
Report
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
3/10
09:00 am
agio
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
Low
Report
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
3/9
11:37 am
agio
Agios Pharmaceuticals: Worthy Of Accumulation [Seeking Alpha]
Low
Report
Agios Pharmaceuticals: Worthy Of Accumulation [Seeking Alpha]
3/5
02:48 pm
agio
Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.
Low
Report
Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.
3/4
09:21 am
agio
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets [Yahoo! Finance]
Low
Report
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets [Yahoo! Finance]
3/4
09:00 am
agio
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
Medium
Report
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
3/3
09:00 am
agio
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
Medium
Report
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
3/2
09:22 pm
agio
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]
3/2
07:35 am
agio
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates [Yahoo! Finance]
Low
Report
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates [Yahoo! Finance]
3/2
07:00 am
agio
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
Low
Report
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
2/14
06:37 pm
agio
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress [Yahoo! Finance]